M Protein, C Protein, Factor V, and APS: Their Roles in Thrombosis and the Newly Identified VITT-Like Disorder

By SWA

Introduction

Blood clotting is a tightly regulated process that involves numerous proteins, including M protein, Protein C, and Factor V. While these proteins have different functions, they all play a role in clotting disorders. Recent research has uncovered a chronic prothrombotic disorder linked to low levels of M protein, which acts as a VITT-like antibody targeting platelet factor 4 (PF4). This condition, now referred to as VITT-like Monoclonal Gammopathy of Thrombotic Significance (MGTS), represents a new disease category requiring specialized treatment approaches.

This article explores the roles of M protein, Protein C, Factor V, and APS (Antiphospholipid Syndrome) in thrombosis and how they connect to this newly identified disorder.

VITT-like Monoclonal Gammopathy of Thrombotic Significance
https://www.nejm.org/doi/10.1056/NEJMoa2415930

Understanding M Protein: A Marker of Plasma Cell Disorders

What is M Protein?

M protein (monoclonal protein) is an abnormal immunoglobulin (antibody) produced by a single clone of plasma cells. Unlike normal antibodies, M proteins serve no immune function and can sometimes cause complications, particularly in plasma cell disorders.

Conditions Associated with M Protein

M protein is commonly detected in serum protein electrophoresis (SPEP) or urine protein electrophoresis (UPEP) and is associated with:

  • Monoclonal Gammopathy of Undetermined Significance (MGUS): A benign condition where low levels of M protein exist without symptoms.
  • Multiple Myeloma: A cancer where plasma cells produce excessive M protein, leading to organ damage.
  • Waldenström’s Macroglobulinemia: A lymphoma characterized by IgM-type M protein.
  • AL Amyloidosis: M protein misfolds, forming amyloid deposits that damage organs.
  • Smoldering Myeloma: A precursor to multiple myeloma with moderate M protein levels but no immediate symptoms.

M Protein’s Role in Thrombosis

While MGUS is generally considered benign, some cases involve thrombosis (blood clot formation) due to the interaction of M proteins with clotting factors. In the newly identified VITT-like MGTS, M protein directly acts as an autoantibody against PF4, leading to persistent clotting problems.

The Newly Identified VITT-Like Disorder: A Chronic Prothrombotic Condition

What is VITT?

Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT) is an immune-mediated clotting disorder triggered by adenoviral vector COVID-19 vaccines (e.g., AstraZeneca, Johnson & Johnson). It is caused by antibodies against PF4, leading to clot formation and low platelet levels.

Chronic VITT-Like MGTS

Unlike acute VITT, VITT-like MGTS is a chronic, long-term condition where:

  • Persistent thrombosis does not respond well to anticoagulants.
  • Intermittent thrombocytopenia occurs, meaning platelets fluctuate over time.
  • M protein acts as the VITT-like antibody, targeting PF4.

Key Findings

  1. M Protein Was Directly Implicated in the Disease

    • Unlike MGUS, where M protein is usually a benign marker, here it was an active pathogenic antibody responsible for clot formation.

  2. Different Immunopathogenesis from Acute VITT

    • Acute VITT is transient, occurring soon after vaccination or adenovirus infection.
    • VITT-like MGTS is chronic, with ongoing clotting issues linked to persistent M protein production.
    • The PF4-binding epitopes on M proteins differed from those seen in acute VITT cases.

  3. New Disease Entity: VITT-Like Monoclonal Gammopathy of Thrombotic Significance (MGTS)

    • This condition represents a new category of monoclonal gammopathy that directly contributes to thrombosis.
    • Unlike typical MGUS, this M protein actively promotes clotting, similar to VITT.

Clinical Implications

  • Standard anticoagulation (heparin, DOACs) may not be effective.
  • Targeted therapies (e.g., anti-CD38 drugs like daratumumab) may be needed to reduce M protein levels.
  • Patients with unexplained thrombosis and low-level M protein should be evaluated for VITT-like antibodies.

M Protein, APS, and Factor V: How They Are Connected

M Protein and Antiphospholipid Syndrome (APS)

APS is an autoimmune disorder where the body produces antiphospholipid antibodies (aPL) that increase the risk of blood clots. While APS and M protein disorders are not directly related, there are some overlaps:

  • Some monoclonal gammopathies (especially MGUS) have been linked to increased clot risk, possibly due to immune system dysfunction or inflammation.
  • In rare cases, MGUS or multiple myeloma can coexist with APS, compounding the clotting risk.

M Protein and Factor V (Leiden & Deficiency)

Factor V is a key clotting factor in the coagulation cascade.

  • Factor V Leiden Mutation: A genetic disorder where Factor V is resistant to Protein C inactivation, increasing clot risk.
  • Factor V Deficiency: A bleeding disorder due to low Factor V levels.

M protein-related disorders can influence Factor V function in two ways:

  1. Exacerbating Factor V Leiden Clotting Risk – If someone has MGUS + Factor V Leiden, the clotting risk is even higher.
  2. Acquired Factor V Deficiency – Some plasma cell disorders cause autoantibodies against Factor V, leading to excessive bleeding.

M Protein vs. Protein C: Differences & Functions

FeatureM ProteinProtein C
What is it?Abnormal monoclonal immunoglobulin (antibody) produced by plasma cells.A natural anticoagulant protein that prevents excessive blood clotting.
FunctionNo normal immune function; may indicate plasma cell disorders.Degrades clotting factors (Factor Va and Factor VIIIa) to regulate coagulation.
Associated ConditionsMGUS, multiple myeloma, Waldenström’s macroglobulinemia, amyloidosis.Protein C deficiency (inherited or acquired), leading to thrombophilia (excessive clotting).
Risk Factor for Clots?Yes, some monoclonal gammopathies increase clot risk.Yes, Protein C deficiency leads to excessive clotting.
Tested By?Serum protein electrophoresis (SPEP), urine protein electrophoresis (UPEP), immunofixation.Blood tests measuring Protein C activity or antigen levels.

How Are They Related?

  • M protein disorders (like MGUS or multiple myeloma) can increase clot risk, potentially interfering with Protein C function.
  • Protein C deficiency leads to higher clot risk, which can be worsened by M proteins.
  • Some plasma cell disorders can cause acquired Protein C deficiency, increasing the risk of deep vein thrombosis (DVT) or pulmonary embolism (PE).

Conclusion

This newly identified VITT-like MGTS disorder highlights a rare but important prothrombotic condition driven by M protein. Unlike MGUS, where M protein is usually benign, here it acts as a pathogenic autoantibody against PF4, mimicking VITT but in a chronic form.

The discovery of this disease has important clinical implications:

  • Patients with unexplained thrombosis and low M protein levels should be tested for VITT-like antibodies.
  • Standard anticoagulation may not be effective, and targeted plasma cell therapies should be explored.
  • This condition represents a new category of monoclonal gammopathy (MGTS) that directly contributes to thrombosis.

Understanding the roles of M protein, Protein C, Factor V, and APS is crucial in identifying and managing complex clotting disorders, especially those that do not respond to traditional treatments.

© 2000-2025 Sieglinde W. Alexander. All writings by Sieglinde W. Alexander have a fife year copy right. Library of Congress Card Number: LCN 00-192742 ISBN: 0-9703195-0-9

Comments

Post a Comment

Popular posts from this blog

Toxic Skin Condition Post-mRNA COVID-19 Vaccination

By SWA
Image
Identifying Severe Skin Conditions Post-Vaccination Following administration of the BioNTech mRNA vaccine, a small subset of individuals may develop severe and complex reactions. These reactions are often misdiagnosed or misunderstood due to their rarity and diverse presentation. This essay examines a case characterized by severe skin conditions, systemic symptoms, and complications such as hypercalcemia and crystal formation. It highlights the need for accurate diagnosis, holistic management, and increased awareness of these rare but significant vaccine-related adverse events. Initial Symptoms and Misdiagnoses Severe symptoms began shortly after the first dose of the BioNTech vaccine, initially presenting as petechiae, diagnosed by a rheumatologist. However, following the second dose, symptoms rapidly escalated, resulting in intense burning pain and thinning of the skin. The skin on the legs and thighs became paper-thin and could tear with the slightest touch, with the affected area e...
Read more

Dysferlin Protein: Key Roles, Genetic Locations

By SWA
Image
The purpose of this article is to share and discuss the details of a new discovery, which is highlighted within: CRISPR-Cas9: A Breakthrough Tool to Repair the DYSF Gene The dysferlin protein plays an essential role in maintaining the integrity of muscle cell membranes, particularly in tissues that endure significant mechanical stress, such as skeletal and cardiac muscles . Encoded by the DYSF gene , dysferlin is indispensable for repairing damaged cell membranes after injury caused by muscle contraction or external forces. This article explores the main locations where dysferlin is produced, its role in muscle repair, and supportive nutritional and therapeutic strategies for individuals with dysferlin deficiency, such as those affected by dysferlinopathies (e.g., Limb-Girdle Muscular Dystrophy Type 2B or Miyoshi Myopathy). Currently, there is no definitive answer as to why the severity of dysferlin protein expression or depletion varies. Do pathogens play a role in the methylation o...
Read more

Is ME CFS connected to Spinal Muscular Atrophy (SMA) or Post Polio?

By SWA
Image
Today, I understand why Spinal Muscular Atrophy (SMA) received little attention, particularly in the mid-50s. This complex and debilitating genetic illness was poorly understood, and patients' symptoms were often minimized or even dismissed. For more information, please visit the Spinal Muscular Atrophy (SMA) page on MalaCards . Even now, many neurologists lack detailed knowledge of SMA, and comprehensive examinations mentioned in research are rarely pursued. In 2008, while investigating permanent adrenal insufficiency, an MRI ordered by my endocrinologist unexpectedly revealed Chiari Malformation II. However, surgery in 2009 brought no improvement. In 2010, a DNA test showed a genetic marker in the ACTN3 gene: https://www.malacards.org/search/results?q=ACTN3%20gene%20and%20Spinal%20Muscular%20Atrophy%20(SMA) A 2015 MRI revealed ankylosing spondylitis, multiple Tarlov cysts, stenosis at L4 and L5, spinal canal narrowing, and widespread degenerative changes. Surgery on L4 and L5 ...
Read more